- ISIN
- US68622P1093
- CUSIP
- 68622P109
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 24, 2020
Highlights
- Market Cap
- $826.91M
- Enterprise Value
- $770.51M
- EPS (TTM)
- -$1.46
- Gross Profit (TTM)
- -$320.00K
- EBITDA (TTM)
- -$140.86M
- Year Range
- $7.23 - $14.93
- Target Price
- $21.75
- ROA (TTM)
- -30.96%
- ROE (TTM)
- -32.54%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ORIC Performance Chart
ORIC Pharmaceuticals, Inc. (ORIC) is down 4.2% since the beginning of the year. At $8 per share, ORIC is trading 47.5% below its 52-week high of $15. Investors who bought $1,000 worth of ORIC shares 5 years ago would now be looking at an investment worth $404.
Loading charts...
Returns By Period
ORIC Pharmaceuticals, Inc. (ORIC) has returned -4.16% so far this year and -6.67% over the past 12 months.
ORIC Pharmaceuticals, Inc.
- 1D
- 2.89%
- 1M
- -18.59%
- YTD
- -4.16%
- 6M
- -28.60%
- 1Y
- -6.67%
- 3Y*
- 13.80%
- 5Y*
- -16.59%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
ORIC Monthly Returns History
Based on dividend-adjusted daily data since Apr 24, 2020, ORIC's average daily return is +0.07%, while the average monthly return is +1.10%. At this rate, an investment would double in approximately 5.3 years.
Historically, 45% of months were positive and 55% were negative. The best month was Dec 2022 with a return of +64.1%, while the worst month was Jul 2020 at -40.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.
On a daily basis, ORIC closed higher 46% of trading days. The best single day was Dec 22, 2022 with a return of +59.7%, while the worst single day was Apr 1, 2026 at -41.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 25.43% | 31.09% | -5.80% | -22.02% | -14.47% | -7.22% | -4.16% | ||||||
| 2025 | 29.12% | -22.94% | -30.51% | 2.33% | 43.08% | 24.24% | -1.77% | 2.61% | 17.30% | 9.67% | -9.73% | -31.14% | 1.36% |
| 2024 | 19.46% | 15.92% | 7.93% | -35.78% | 1.81% | -21.36% | 58.42% | -7.41% | -1.16% | -8.49% | 5.54% | -18.48% | -12.28% |
| 2023 | -3.90% | -21.73% | 28.67% | -9.30% | -2.51% | 53.97% | 7.73% | 7.18% | -32.48% | 10.74% | 17.91% | 16.46% | 56.20% |
| 2022 | -32.72% | -21.54% | -31.19% | -37.83% | 0.60% | 34.13% | -18.30% | -5.46% | -7.51% | -16.56% | 34.46% | 64.07% | -59.93% |
| 2021 | -13.38% | 10.50% | -24.38% | -1.51% | -5.30% | -22.58% | -5.88% | 32.67% | -5.34% | -29.99% | -5.46% | 6.21% | -56.57% |
Benchmark Metrics
ORIC Pharmaceuticals, Inc. has an annualized alpha of -0.67%, beta of 1.10, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since April 27, 2020.
- This stock participated in 209.04% of S&P 500 Index downside but only 86.92% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -0.67%
- Beta
- 1.10
- R²
- 0.05
- Upside Capture
- 86.92%
- Downside Capture
- 209.04%
Return for Risk
Risk / Return Rank
ORIC ranks 40 for risk / return — below 40% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ORIC Pharmaceuticals, Inc. (ORIC) and compare them to S&P 500 Index.
| ORIC | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.33 | ||
| Sortino ratioReturn per unit of downside risk | -2.59 | ||
| Omega ratioGain probability vs. loss probability | 1.07 | 1.41 | -0.33 |
| Calmar ratioReturn relative to maximum drawdown | -0.14 | 2.93 | -3.07 |
| Martin ratioReturn relative to average drawdown | -0.29 | 13.52 | -13.81 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the ORIC Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ORIC Pharmaceuticals, Inc. was 93.87%, occurring on Nov 7, 2022. The portfolio has not yet recovered.
The current ORIC Pharmaceuticals, Inc. drawdown is 80.30%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -93.87%Nov 2022 | 1y 10mo | — | 5y 5moDec 2020 - now |
2020 bear market2020 | -48.85%Sep 2020 | 3mo | 2mo 28d | 5mo 28dJun 2020 - Dec 2020 |
2020 bear market2020 | -20.43%May 2020 | 12d | 6d | 18dMay 2020 - Jun 2020 |
2020 correction2020 | -16.16%Jun 2020 | 13d | 3d | 16dJun 2020 - Jun 2020 |
2020 pullback2020 | -8.05%May 2020 | 1d | 1d | 2dMay 2020 - May 2020 |
Drawdown Indicators
| ORIC | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.87% | -56.78% | -37.09% |
Max Drawdown (1Y)Largest decline over 1 year | -48.13% | -9.10% | -39.03% |
Max Drawdown (3Y)Largest decline over 3 years | -73.46% | -18.90% | -54.56% |
Max Drawdown (5Y)Largest decline over 5 years | -90.33% | -25.43% | -64.90% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -80.30% | -0.74% | -79.56% |
Average DrawdownAverage peak-to-trough decline | -67.74% | -10.72% | -57.02% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.26% | 1.97% | +21.29% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ORIC Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ORIC Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ORIC in comparison with other companies in the Biotechnology industry. Currently, ORIC has a P/B value of 2.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ORIC
Add ORIC Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ORIC